Using RWE To Get To Insights — And Action — Faster

By Ivy Weng, MD, Head of Clinical Development and RWE/HEOR

The terms "real-world evidence" (RWE) and "real-world data" (RWD) have become commonplace in discussions within the healthcare landscape. Stakeholders such as providers, health plans, public health officials, and Life Sciences companies increasingly recognize the value of analytics in comprehensively tracking individual engagement with the healthcare system.

However, amid the widespread recognition of their importance, there still exists a considerable degree of confusion about how RWE is actively reshaping processes across the entire product life cycle. This transformative impact extends from the early stages of drug development through the intricacies of clinical trials and ultimately to the complex commercialization landscape. To demystify this intersection of healthcare and data analytics, this narrative will delve into three recent examples that vividly showcase the formidable power of real-world evidence in these critical phases of the healthcare journey.